Clinical Trials · NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 45
- Start date
- Mar 2019
- Locations
- 1 site, Singapore
- Primary endpoint
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration